Introduction
Tumor progression towards the malignant phenotype involves many changes in gene expression, which result in the substitution of epithelial characteristics for those of the fibroblastic or mesenchymal cell (Gilles and Thompson, 1996) . This transition is known as the epithelium to mesenchyme transition or EMT. The intermediate filament protein (IFP) vimentin is a wellknown marker for the mesenchymal cell. Vimentin is turned on during the EMT, while the normal epithelialspecific IFP, cytokeratin, is downregulated and/or switched to a different isoform. The parental MCF7 cell line represents a breast cancer cell line, which has not yet progressed to the metastatic state and thus does not express vimentin. Previously, it was shown that if the MCF7 cell line was stably transformed with c-Jun (MCF7Jun), many changes in gene expression occurred, which are thought to mimic those displayed in the clinic (Smith et al., 1999) . Briefly, MCF7Jun cells exhibit a change in morphology, increased mobility, increased chemoinvasion in vitro, and can form tumors in nude mice. A comparative hybridization of 588 genes yielded 21 genes, which were either upregulated or downregulated by c-Jun expression (Rinehart-Kim et al., 2000) . One group of four genes, which included the macrophage migration inhibitory factor (MIF), p16-INK4A, EMMPRIN, and vimentin, consistently yielded high levels of expression in all the three MCF7Jun cell lines analysed. Of these, the expression of vimentin was the greatest. This activation was subsequently confirmed by direct measurement of RNA (Northern blot) as well as protein levels (Western blot). In retrospect, perhaps this result was not surprising, as previously vimentin expression was shown to be activated in many breast cancer cell lines, which had progressed to the metastatic state, were ER À , and could form tumors in nude mice (Thompson et al., 1992) . Likewise, a correlation between the expression of MIF or p16-INK4A and tumor progression has been noted (Mitchell and Bucala, 2000; Milde-Langosch et al., 2001) . However, it was apparent that determining what controls vimentin expression in these cells could lead to an understanding of what contributes to changes in gene expression that occurs during transformation to the malignant state.
Previous studies have implicated that the activator protein (AP1) transcription factor is important in tumor progression (Young et al., 1999) . The AP1 family of basic, leucine-zipper (bZIP) proteins is composed of heterodimers of Jun (c-Jun, JunB, JunD), Fos (cFos, FosB, Fra1 and Fra2) or ATF (ATF-1, ATF-2)/CREB, or homodimers of Jun/Jun (Angel and Karin, 1991; Rahmsdorf, 1996) . Given this large number of interactive partners, it is no wonder that the AP1 family can mediate the expression of a wide variety of genes that could contribute to tumor promotion. In the MCF7Jun stably transformed cell, overexpression of c-Jun resulted in a decreased expression of JunB and a corresponding increase in Fra1 (Smith et al., 1999) . Previously, tandem AP1 sites were located around position À650 in the 5 0 -end of the vimentin gene (Rittling et al., 1989; Sommers et al., 1994) . These have been shown to be important for the serum and TPA inducibility of the vimentin gene. EMSAs with nuclear extract (NE) from the MCF7Jun cells displayed at least two shifted bands, both of which could be supershifted with antibodies to c-Jun and Fra1, but not JunB, c-Fos, or p16 as a negative control (Rinehart-Kim et al., 2000) . However, the complete impact of c-Jun on vimentin expression was not fully analysed. Here, we have investigated the mechanism(s) by which c-Jun expression results in an exceptionally high level of vimentin expression in the MCF7Jun cell line.
Results

Localization of DNA sequences required for c-Jun induction of vimentin gene expression
Several cis-acting DNA elements have been delineated within the 5 0 -end of the human vimentin gene by the transient transfection of various promoter fragments fused to the reporter gene, CAT, in various cell types ( Figure 1a ). Negative numbers indicate the 5 0 -end start nucleotide for each promoter region extending to þ 72 from the transcriptional start site, as determined for the vimentin gene. By this approach, GC-box1 was found to be indispensable for basal expression and to bind Sp1 and/or Sp3 (Zhang et al., 2003) . Mutation of this sequence within À261/ þ 72CAT resulted in little reporter gene activity, which did not increase with the inclusion of additional 5 0 -end DNA up to position À1114 (Izmailova et al., 1999a) . Other DNA elements include a TATA box, a PEA3 site (Chen et al., 1996) , an NF-kB element (Lilienbaum and Paulin, 1993) , a proximal silencer (PS), which binds the repressor protein ZBP-89 (Wieczorek et al., 2000) , and an antisilencer element (ASE) (Izmailova and Zehner, 1999b) .
To determine if the tandem AP1 sites were solely responsible for the overexpression of vimentin, the various vimentin-promoter CAT gene constructs were transiently transfected into the MCF7Jun cell line, 2-31 ( Figure 1b , white box). As expected, considerable reporter gene activity is seen with the À757/ þ 72CAT construct containing the tandem AP1 sites plus other DNA elements. More importantly, removal of the AP1 sites as found in the À353/ þ 72CAT or À261/ þ 72CAT constructs still yields appreciable activity above that of the promoterless p18CAT control vector, indicating that the AP1 elements are not all that are contributing to gene expression. Analysis of these same CAT constructs in MCF7 cells, stably transformed with the empty neo vector (MCF7neo), displayed no vimentin-promoter activity above that of the p18CAT control vector (Figure 1b , gray box). This result confirms that it is not the stable transformation process itself that leads to vimentin expression, but that activation is dependent upon the stable expression of the c-Jun oncogene. Next, we coexpressed TAM67, the dominant-negative mutant of c-Jun, to determine if TAM67 could reverse this c-Jun affect (Figure 1b , black box). TAM67 lacks the transactivation domain of c-Jun (amino acids 1-122), and thus should function as a dominant negative to block wild-type c-Jun binding to the AP1 site (Brown et al., 1996) . However, it retains the DNA binding and leucine-zipper region (bZIP) of c-Jun (see Figure 5a) . Surprisingly, coexpression of TAM67 yields even higher (Figure 1c) . No vimentin mRNA is detected in the parental MCF7 or MCF7neo cell line, as has been verified by us and others (Sommers et al., 1989; Thompson et al., 1992; Stover et al., 1994) , whereas considerable vimentin mRNA is present upon stable transformation with c-Jun (Figure 1d ).
To investigate further what might be required for the activation of vimentin gene expression, we carried out a similar analysis in COS-1 cells. COS-1 cells were chosen because the endogenous level of c-Jun is low (see Figure 5c ). Moreover, COS-1 cells exhibit a high transfection frequency, and usually respond to the expression of additional regulatory factors. If reporter gene activity increased with the coexpression of c-Jun or other jun/fos family members, we might be able to determine what DNA elements and other proteins are involved in enhancing vimentin expression. Thus, we examined the effect of c-Jun/TAM67 expression on the various vimentin 5 0 -end CAT constructs (Figure 2a) . Overall, the pattern of expression was similar, but CAT activity was less than that exhibited by the MCF7Jun cells ( Figure 1b , white box), with the À757/ þ 72CAT construct yielding the highest level of expression and À353/ þ 72CAT or À261/ þ 72CAT considerably less ( Figure 2a , white boxes). However, mutation of the AP1 elements within the À757/ þ 72CAT construct (À757/ þ 72mAP1CAT) resulted in little reduction in reporter gene activity over that of the wild-type construct, which suggests that the increased activity displayed by À757/ þ 72CAT compared to À353/ þ 72CAT or À261/ þ 72CAT must be due to other elements than just the AP1 sites. Greater activity was obtained upon the coexpression of c-Jun (Figure 2a , gray boxes), which now equals the expression level obtained in MCF7Jun cells (Figure 1b) . Either construct À353/ þ 72CAT (10-fold) or À261/ þ 72CAT (11-fold) greatly exceeded that displayed by À757/ þ 72CAT containing the AP1 sites (only twofold). Interestingly, cotransfection of the dominant-negative mutant, TAM67 (Figure 2a , black boxes), with either the À261/ þ 72CAT or À353/ þ 72CAT constructs yields 2-5-fold more activity than c-Jun and 26-48-fold higher activity than the vectortransfected control. Even the À757/ þ 72mAP1CAT mutant yielded fourfold more activity with TAM67 than c-Jun. Interestingly, only a minimal increase was seen with the cotransfection of JunB and the À261/ þ 72CAT construct (Figure 2b ). Thus, this increase is specific to c-Jun.
To determine what DNA elements within vimentin's promoter might be required for the AP1-independent induction by c-Jun or its dominant-negative mutant TAM67, we constructed mutants of the À353/ þ 72CAT construct, which contained either a mutant GC-box1 Figure 3a) . In all cases, nucleotide changes were selected, which were known to be inactive for factor binding (Zhang et al., 2003) . To our knowledge, these DNA sequences are the only other activator elements thought to be important for vimentin gene expression downstream of the PS element in construct À353/ þ 72CAT (Figure 1a) . Cotransfection of TAM67 with À353/ þ 72CAT or the various mutant constructs shows that GC-box1 is absolutely required for the TAM67 Is Sp1 required for c-Jun induction of vimentin gene expression?
From our previous studies, it was apparent that GC-box1 binds the activator Sp1 (or Sp3), and this interaction is absolutely required for basal levels of gene expression (Izmailova et al., 1999a; Zhang et al., 2003) . Next, we monitored the effect of c-Jun and/or Tam67 on vimentin's proximal promoter activity. Cotransfection of either Sp1 or c-Jun alone in COS-1 cells shows an eightfold increase in activity of the À353/ þ 72CAT construct ( Figure 3b ). Sp1 plus c-Jun yields a 35-fold increase, which is close to that of TAM67 alone. Sp1 plus TAM67 yields a 55-fold increase above that of the vector alone. Similar results were seen in HeLa cells, where again cotransfection of Sp1 with c-Jun or TAM67 yields the highest activity, 15-fold above that of endogenous levels (data not shown). Removal of the Ser/Thr-rich region, but inclusion of the entire Gln-rich region, increases gene activity to 10-fold, whereas both regions together yield 11-fold. Similarly, region A alone (Dint349) yields a 13-fold increase. But, an Sp1 deletion containing only the second Ser/Thr-rich and a small portion of the adjacent Gln-rich region (516c-Dint266) yields no activity ( Figure 4c , far right). Western blots confirm that TAM67, c-Jun, and Sp1 including its various deletions are equally expressed (Figures 4d and e) . From these results, it appears that c-Jun requires either region A or B to enhance Sp1 activity and that the Gln-rich subregion is the most important, since construct 440c-Dint122 is as active as 516c-Dint112 and deletion of a C-terminal section of the Gln-rich region in Dint162 reduces the activation to only fourfold, compared to 10-13-fold. Interestingly, the individual subdomains of Sp1 combined with insertion of three negatively charged amino acids after residue 265, which renders the protein incapable of DNA binding (Brown et al., 1996) . However, deletion of the leucine-zipper domain (LZM-1) completely eliminates the ability of c-Jun to enhance reporter gene expression, leading us to conclude that this domain must be required for activating Sp1. Western blots confirm the comparable expression of cJun and its mutant derivatives in transfected COS-1 cells (Figure 5c ).
In vitro binding experiments confirm the interaction of c-Jun and Sp1
Expression studies suggest that Sp1 and c-Jun must interact to enhance vimentin gene expression. Electrophoretic mobility shift assays (EMSAs) with EMSAs suggest that Sp1 and c-Jun may be binding to GC-box1 together, since one major band is detected on these gels (Figure 6a or b) . However, we cannot detect the presence of c-Jun by antibody recognition in EMSAs, although the c-Jun antibody is perfectly capable of recognizing c-Jun bound to vimentin's AP1 elements. Perhaps, the failure to recognize c-Jun in a GC-box1/Sp1/c-Jun complex is because c-Jun is masked by Sp1 and inaccessible to antibody binding. To address this issue, we carried out DNA precipitation assays (DNAP) with double-stranded (ds) DNA encompassing vimentin's proximal promoter region containing a CAAT box, a GC-rich region, and the TATA box, in addition to GC-box1 (Zhang et al., 2003) . This dsDNA was endlabeled with biotin, and incubated with wholecell extracts (WCE) from COS-1 cells (Figure 7 
Discussion
Previously, the tandem AP1 sites within vimentin's promoter were shown to be important for the serum and TPA inducibility of the vimentin gene (Rittling et al., 1989) , as well as its expression in vimentin-positive, breast cancer cell lines (Sommers et al., 1994) . Initially, this appeared consistent with the 3-11-fold enhanced expression of construct À757/ þ 72CAT versus À353/ þ 72CAT or À261/ þ 72CAT in MCF7Jun or COS-1 cell lines (Figures 1b and 2a) . However, mutation of just the AP1 sites within the À757/ þ 72mAP1CAT construct or deletion of these sites in the À353/ þ 72CAT or À261/ þ 72CAT constructs still yielded considerable reporter gene activity. Cotransfection of cJun or TAM-67 in S2 (Figure 4) or COS-1 (Figures 2a,  3b , and 5) cells, which have either no or low amounts of endogenous c-Jun protein, showed a considerable increase in reporter gene activity with constructs lacking the AP-1 sites. Thus, there must be another mechanism by which c-Jun can activate the vimentin promoter. Our results indicate that c-Jun is able to activate vimentin gene expression by two independent methods: (1) binding of c-Jun to tandem AP1 sites within vimentin's upstream promoter region, and (2) by direct interaction with the activator Sp1 in binding to GC-box1.
To date, the interaction of c-Jun and Sp1 has been found to be important in the regulation of the lipoxygenase (Chen and Chang, 2000) , p21 (Kardassis et al., 1999; Wang et al., 2000) , cPLA 2 (Blaine et al., 2001) , and neuronal nicotinic acetylcholine receptor (Melnikova and Gardner, 2001) genes. For p21, this (Kardassis et al., 1999) or repressed (Wang et al., 2000) gene expression in different cell types, suggesting that a c-Jun/Sp1 interaction might be promoter-specific and does not always confer activation. However, none of these promoters contained AP1 sites, but all required a GC box to detect c-Jun-enhanced expression of the appropriate reporter gene. More recently, the SPARC (osteonectin) gene has been shown to be activated by c-Jun via an Sp1-'like' complex (Briggs et al., 2002) . Like vimentin, the SPARC gene contains both tandem AP1 sites and a GC box. In the former cases, gene expression was usually induced by molecules such as EGF, PMA, or NGF by various signaling pathways, which resulted in activating c-Jun. For vimentin and SPARC, gene expression is being activated by the stable expression of c-Jun in the MCF7 cell line (MCF7Jun), where the parental cell did not express either protein. Although we are not supplying any additional stimulus, overexpression of c-Jun by itself must be activating similar signal transduction pathways, which in turn activate gene expression. Moreover, this activation can be mimicked in COS-1 or S2 cells when c-Jun is similarly overexpressed, which permits further investigation into the requirements for activation (Briggs et al., 2002) . In addition to c-Jun binding to AP1 elements, we detect a second mechanism of c-Jun activation, which is dependent on GC-box1 binding and is independent of AP1 site binding. Mutation of the GC-box1 sequence in À353mSp1 completely eliminates c-Jun induction (Figure 3) . Moreover, DNA-protein binding, as detected in EMSAs (Figure 6 ) or DNAP assays (Figure 7) , is dependent on a functional GC-box1 sequence. However, our results indicate that c-Jun itself is not binding to GC-box1 DNA. The sequence of GCbox1 has no similarity to an AP1 element, and there is no evidence that c-Jun can bind to a GC-box sequence. In fact, transfection of the À353/ þ 72CAT construct with c-Jun alone yields little reporter gene activity in S2 cells (Figure 4c) , which supports the fact that c-Jun is incapable of binding to vimentin's proximal promoter region in the absence of AP1 elements and enhancing gene expression minus Sp1. Furthermore, destruction of c-Jun's DNA-binding domain does not eliminate its ability to activate reporter gene expression in the presence of Sp1 ( Figure 5 ). Like others, we were able to detect a supershift of the GC-box1 complex with antibodies to Sp1, but not with antibodies to c-Jun (Kardassis et al., 1999; Briggs et al., 2002) . However, for the first time, we were able to confirm the presence of both Sp1 and c-Jun bound to GC-box1 DNA by DNAPs. Mutation of the GC-box sequence within vimentin's proximal promoter region (92 bp) resulted in negligible c-Jun binding in the absence of Sp1 (Figure 7) . Thus, DNA-binding specificity is being conferred via Sp1's recognition of the GC-box1 sequence. Coimmunoprecipitation studies indicate that Sp1 and c-Jun can interact in solution and DNA need not be present to detect this interaction (Figure 8) . Altogether, these results suggest that c-Jun and Sp1 may first interact and then subsequently bind to DNA, displaying an enhanced ability to recruit the transcription complex, although the exact sequence of these events remains to be determined.
Previously, GST-interaction studies showed that the bZIP (LZM) region of c-Jun was required to bind to either the homologous Gln-rich subregion of region A or B of Sp1 (Kardassis et al., 1999) . Cotransfection of Sp1 and c-Jun expression plasmids with the p21 promoter fused to the CAT gene showed that the Glnrich portion of region B was sufficient to support c-Jun activation. However, the Sp1 protein used in this analysis was a fusion between the GAL4 DNA-binding domain and various Sp1 deletions using a GAL4 promoter. Thus, the binding of Sp1 was not by its own zinc-finger domain binding to a GC-box sequence, but rather by a foreign DNA-binding domain and DNA element. In addition, the activity of region A was never tested by itself, resulting in the impression that region B might be the most important. Here, we recast this experiment using native Sp1 and derivates thereof, to better assess the requirements of c-Jun binding to Sp1, while maintaining Sp1's native zinc-finger domain binding to vimentin's GC-box1 ( Figure 4) . As noted before, the presence of only the second Ser/Thr-rich region and a small portion at the N-terminus of the Glnrich domain yielded no gene activation in either the presence or absence of c-Jun (Kardassis et al., 1999) . Obviously, the presence of at least one Gln-rich region is required to promote basal transcription regardless of the presence or absence of c-Jun. Our results suggest that the Gln-rich domain of either region A or B is sufficient to interact with c-Jun, and perhaps region A is slightly more active than region B, which differs from the former study. Moreover, we confirm that this interaction requires the leucine-zipper region (LZM) of c-Jun. The fact that TAM-67 is more active than c-Jun (Figures 1b, 2a, 3b, and 5) and contains the leucine-zipper region, but lacks the transactivation domain, further supports these findings. Altogether, we conclude that the LZM region of c-Jun can bind to either Gln-rich region of Sp1 to further activate transcription.
Although it was previously shown that only the bZIP region of c-Jun was required to bind to Sp1 in vitro, the effect of this deletion on gene expression was never addressed in vivo. In retrospect, perhaps it is not surprising that TAM67 would be as effective as c-Jun, but it was totally unexpected that TAM67 would be an even more effective inducer of gene expression in cells. Here, it would appear that removal of approximately 1/3 of the NH-terminus of c-Jun including the phosphorylation sites for JNK has created a molecule that functions better in coactivating Sp1. Interestingly, cPLA2 gene expression was also enhanced by either cJun or v-Jun, which lacks the JNK docking domain (Blaine et al., 2001) . From these studies, it was suggested that the increased expression of c-Jun may be more important than direct phosphorylation of the protein.
Since TAM-67 lacks the Ser-63 and Ser-73 phosphorylation sites, but yields a 4-10-fold induction over that of c-Jun in COS-1 cells (Figure 2b) , we concur that phosphorylation of c-Jun is not required for synergy (Figure 4 ). However, we found that Jun B expression did not significantly enhance gene expression in COS-1 cells. This was not the case for the p21 promoter where JunB, JunD, ATF-2, or coexpression of c-Jun/ATF-2 enhanced promoter activity (Kardassis et al., 1999) . Although JunB possesses a similar bZIP region, our result suggests that slight functional differences must exist, which may be promoter-specific, and thus effect synergism with Sp1. Previously, it was shown that c-Jun expression in breast cancer cell lines correlated with vimentin expression, whereas Jun B or Jun D did not (Sommers et al., 1994) . Our results would concur that c-Jun is the important contributor to vimentin expression. It has been postulated that TAM67 is an effective inhibitor of c-Jun activation, making it a feasible therapy for controlling gene expression in cancer cells (Li et al., 2000) . However, from our data this may be promoter-specific. For vimentin, gene expression might be further enhanced and not repressed by expressing TAM67. Thus, the usefulness of TAM67 as an overall negative regulator of c-Jun activity remains to be seen.
Previously, it was suggested that Sp1 supplies a platform for the binding of activated c-Jun (Chen and Chang, 2000) . This might imply that it is the transactivation domain of c-Jun, not Sp1, that is serving to recruit the transcription apparatus. Our studies would suggest that this is not the case. Since TAM-67 lacks the transactivation domain, but functions better than c-Jun in activating vimentin gene expression, it is more likely that the transactivation domains of Sp1 remain the important determinants in recruiting the transcription complex. This effort is further enhanced by TAM67, which, perhaps by lacking a competing activation domain, produces a conformational change in Sp1 that facilitates its ability to recruit the transcription apparatus. This would support a model whereby c-Jun binds to Sp1 in solution, and then the complex binds DNA yielding the single band detected in EMSAs (Figure 6 ). Previously, it has been shown that the Gln-rich domain of Sp1 interacts with Drosophila TAF II 110 (Hoey et al., 1993) or mammalian TAF II 130 (Saluja et al., 1998) . Interestingly, this is same domain that interacts with cJun (or TAM-67), and we have shown that this domain is crucial for vimentin gene expression (Zhang et al., 2003) . How these proteins physically interact at the same site to enhance recruitment of the transcription complex and whether there are other unknown components of this complex remains an intriguing question.
In summary, it appears that c-Jun synergizes with Sp1 to enhance its subsequent binding to a GC-box element and only the leucine-zipper region of c-Jun is required. Thus, c-Jun is acting like a coactivator, since it does not bind DNA directly, but only via Sp1. Such synergism between Sp1 and the related protein Sp3 has been proposed, although in this case both proteins can bind DNA (Bakovic et al., 2000) . Lastly, unlike many other genes, c-Jun has the possibility of activating vimentin gene expression, both by the classical method of c-Jun binding as either a homodimer or heterodimer to its tandem AP1 sites as well as by the independent, synergistic interaction with Sp1, thereby enhancing its ability to recruit the transcription complex. Perhaps, it is this dual mechanism of activation that accounts for the extremely high level of vimentin expression detected in the MCF7Jun cell line. It will be interesting to note as more Sp1-regulated genes are examined, what other genes might share dual regulation by c-Jun as vimentin and now SPARC. Such a dual mechanism of action could greatly affect levels of gene expression.
Materials and methods
Cell cultures
The c-Jun stably transformed MCF7 (MCF7Jun) cell line 2-31 and its neomycin control line (7-1) were provided by Dr Michael Birrer (NCI/NIH). Cells were grown in improved MEM Zn option media (Invitrogen Corporation), supplemented with 10% heat-inactivated fetal bovine serum (FBS), penicillin (100 U/ml), and streptomycin (50 mg/ml). The COS-1 cell line (from ATCC) was maintained in DMEM (Invitrogen Corporation) with glutamine, supplemented with 10% FBS, penicillin (100 U/ml), and streptomycin (50 mg/ml). The Drosophila S2 cell line (from Invitrogen Corporation) was derived from a primary culture of late stage (20-24 h) Drosophila melanogaster embryos (Schneider, 1972) . S2 cells were maintained in Drosophila medium with 10% FBS and 1% penicillin/streptomycin (Invitrogen Corporation).
Plasmids
Various 5
0 -deletion constructs À757/ þ 72, À353/ þ 72, or À261/ þ 72 and site-mutated constructs (À353/ þ 72mNF-kB, À353/ þ 72mPEA3, À353/ þ 72mSp1) of the human vimentin promoter were fused to the CAT gene as previously described (Wieczorek et al., 2000; Zhang et al., 2003) . The pCMV-c-Jun plasmid and the various mutants (TAM67, DBM-3, and LZM-1) were kindly provided by Dr Michael Birrer (NCI/NIH), pCMV-Sp1 by Dr Juanita Merchant (University of Michigan), pPac-b-gal, pPacSp1, and the various deletion constructs of Sp1 by Dr Robert Tjian (UC-Berkeley), and pPac-c-Jun by Dr John Noti (Guthrie Res. Inst.). TAM67 was cloned by PCR using pPac-c-Jun as template and the two primers 5 0 -GAACT GCACAGCCAGAAC-AC-3 0 and 5 0 -GGCCGGATCCCACA GCCAGAACAC-3 0 . The PCR product was cloned into a pPac vector at BamHI and XhoI sites. The sequence of all clones was verified by DNA sequencing.
Cell transfection and CAT assay
COS-1 or S2 cells were transiently transfected using the calcium phosphate/DNA coprecipitation method. MCF7Jun cells were transfected with Effectenet Transfection Reagent (Qiagen) according to the manufacturer's recommended protocol. Cells (3 Â 10 5 ) were plated in one well of a six-well plate, incubated overnight, and transfected with either 1 mg of plasmid DNA for calcium phosphate coprecipitation or 200 ng for transfection with effectene. The total amount of DNA transfected was kept constant by supplying vector DNA alone. After transfection (48 h), cell lysates were prepared by the freeze/thaw method. pCMV-b-gal was cotransfected to serve as an internal control for transfection efficiency. 
Nuclear and WCE preparation
NEs were prepared from MCF7neo or MCF7Jun cells by the method of Dignam (Dignam et al., 1983) . WCEs were prepared from COS-1 cells transiently transfected with Sp1, c-Jun, and/or TAM67 by the freeze/thaw method. WCEs for immunoprecipitation and Western blot analysis were prepared by resuspending the cells in 1 Â lysis buffer (20 mm HEPES, pH 7.9, 420 mm NaCl, 1.5 mm MgCl 2 , 0.2 mm EDTA, 25% glycerol (v/v), 0.5 mm phenylmethylsulfonyl, 1 mm orthovanadate, and protease inhibitor cocktail at 10 ml/1 ml of extract). The protein concentration was measured using the BCA Protein Assay Kit (PIERCE).
Electrophoresis mobility shift assay (EMSA)
For EMSAs, the following DNA fragments were synthesized: (1) a GC-box1 sequence of 37 bp (5 0 -GGGATGGCAGTGG GAGGGGACCCTCTTTCCTAACGGG-3 0 ) corresponding to the region from À86 to À49 of the human vimentin promoter, and (2) the API sequence of 37 bp (5 0 -GGGCGCGGTGAGTCA CCGCCGG TGACTAA GCGA CCCC-3 0 ) corresponding to the region À762 to À725 of the promoter with the tandem API elements underlined ds DNA (50 pmol) was 32 P-labeled using polynucleotide kinase and [ 32 Pg-] ATP. For the binding reaction, 100 fmol of 32 P-labeled DNA was incubated with 1 mg of poly dI-dC and 10 mg of NE or 20 mg of WCE in a buffer containing 10 mm Tris-HCl (pH 7.5), 50 mm NaCl, 1 mm dithiothreitol, 1 mm Na 2 EDTA and 10% (v/v) glycerol in a final volume of 20 ml. Protein-DNA complexes were separated on a 4% nondenaturing polyacrylamide gel (PAGE). Electrophoresis was carried out in 0.5 Â TBE buffer for 2 h at 170 V at 41C. The gel was dried and placed on XAR film overnight at À701C with an intensifying screen. For competition and supershift assays, a 25-50-fold excess of unlabeled DNA fragment or 2 mg of antibody to Sp1 (Santa Cruz, SC-58X), c-Jun (Santa Cruz, SC-44X) or normal rabbit IgG (Santa Cruz, SC-2027) was incubated at room temperature for 30 min with the NE before adding the 32 Plabeled DNA.
DNAP assays using biotinylated ds oligonucleotides
COS-1 cells were harvested 48 h after transfection with pCMVSp1 alone or plus pCMV-c-Jun, and 500 mg of WCE used for the DNAP assay. Biotinylated DNA was prepared by PCR with the primers 5 0 -GCTAGGTCCCGATTGGCT-3 0 and 5 0 -CGAGGGCGCTGTTTTTAT-3 0 . DNA fragments from À353/ þ 72CAT and À353/ þ 72mSp1CAT digested with EcoR1 served as templates for the PCR reactions. The resulting PCR product is 92 bp in length and includes the CAAT and TATA box and either wild-type GC-box1 or mutant GC-box1 as indicated. DNAP assays were performed as described (Zhang et al., 2003) .
Immunoprecipitation and Western blots
WCE (1 mg) was mixed with 5 mg of antibody and 50 ml of protein A/G plus agarose in 1 Â lysis buffer, as described above, and incubated with rocking overnight at 41C. The beads were washed three times with RIPA buffer (50 mm TrisHCl, pH 7.5, 1% IGEPAL CA-630 (v/v), 150 mm NaCl, 0.5% sodium deoxycholate). Antigen-antibody complexes were removed from the beads by boiling in 1 Â SDS sample buffer. The proteins were separated on a 10% SDS-PAGE gel and transferred to nitrocellulose membrane by electrophoresis. The membrane was blocked in TBST with 5% nonfat milk for 1 h at room temperature, and then incubated with the primary antibody for 1 h at 371C. The membrane was washed three times in TBST and incubated with horseradish peroxidaseconjugated secondary antibody. The specific antigen-antibody interactions were detected using an ECL kit (Amersham). The antibodies used for immunoprecipitation and Western blot analysis are as follows: a monoclonal antivimentin (clone V19) from Sigma (V-6630), a polyclonal anti-Sp1 (H225) from Santa Cruz (SC-14027), and a polyclonal anti-c-Jun (D) from Santa Cruz (SC-44).
